Printer Friendly

ROBERTS PHARMACEUTICAL CORPORATION RECEIVES UK APPROVAL FOR SOMAGARD

 EATONTOWN, N.J., April 22 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) today announced that the United Kingdom regulatory authorities have granted formal approval for SOMAGARD(R) (deslorelin) for the treatment of Central Precocious Puberty (CPP), a childhood disorder characterized by the early onset of sexual development associated with puberty. Roberts UK subsidiary company, Monmouth Pharmaceutical, Ltd., will launch the drug in the near future and will promote the product to pediatric endocrinologists who specialize in the treatment of this disease.
 SOMAGARD is an endocrine drug belonging to the class known as LHRH superagonists and is the first of this class to be approved for CPP in the UK. Roberts has established a franchise in the endocrine market and now markets Supprelin(R) for CPP in the United States. Following the approval for CPP, the UK regulatory authorities are now also considering SOMAGARD for the treatment of prostate cancer. In 1992, SOMAGARD was approved for the treatment of prostate cancer in the Republic of Ireland.
 "We are delighted to be able to build on our expertise in this area and extend our endocrine business with another new product in this field," said Dr. Robert A. Vukovich, Roberts president and chief executive officer. "With the backing of two member states of the European Economic Community (EEC) behind SOMAGARD, we will have the option to use the EEC central regulatory system to speedily apply for registrations in other EEC countries. This is our first approval in the UK for a new chemical entity and this approval demonstrates our growing registration capabilities," added Dr. Vukovich. "We already have a well established subsidiary in the UK, marketing prescription medicines for use in hospitals and general practice as well as nonprescription medicines in the over-the-counter sector."
 Roberts Pharmaceutical is an international pharmaceutical company focusing on the acquisition and development of high-potential, undervalued, late-stage development products and the acquisition of currently marketed prescription and nonprescription products. Roberts products are currently marketed in seven countries with operating subsidiary companies in the United States, Canada, and the United Kingdom. Roberts has seven drugs in late stage clinical development and currently markets over 80 different products for urological therapy, pain management, cough/cold, gastrointestinal disease, endocrine disorders and dermatological conditions.
 -0- 4/22/93
 /CONTACT: Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182/
 (RPCX)


CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU:

TS-OS -- NY080 -- 9494 04/22/93 13:09 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 22, 1993
Words:402
Previous Article:CALIFORNIA FEDERAL BANK DECLARES FIRST DIVIDEND ON PREFERRED STOCK
Next Article:TURNER CONSTRUCTION COMPANY TO BUILD NEW JAIL FACILITY IN ATLANTA
Topics:


Related Articles
ROBERTS PHARMACEUTICALS NOTIFIED OF AMATINE APPROVABILITY IN NEW ZEALAND
ROBERTS RECEIVES FDA APPROVAL TO COMMENCE CLINICAL TRIALS WITH DRUG FOR PROSTATE CANCER
IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION FOR VERAPAMIL
IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION FOR VERAPAMIL
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES CANADIAN REGULATORY APPROVAL FOR AGRELIN(R) TREATMENT IND
ROBERTS PHARMACEUTICAL SUBMITS NEW DRUG APPLICATION TO FDA FOR URINARY INCONTINENCE DRUG
ROBERTS PHARMACEUTICAL CORPORATION DRUG TO RECEIVE HIGH-PRIORITY EC REGULATORY REVIEW
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES REGULATORY APPROVAL TO SELL PRO-AMATINE UNDER TREATMENT USE AND SALE REGULATIONS
ROBERTS PHARMACEUTICAL CORPORATION AND FDA TO MEET TO DISCUSS ACCELERATED APPROVAL OF PROAMATINE
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES FDA TO APPROVE THE COMPANY'S FIRST PIPELINE DRUG, PROAMATINE, UNDER THE ACCELERATED PROCESS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters